Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis

Arumugam Manoharan; Rosalie Gemmell; Lauren Cavanaugh; Noor Shadood

doi:10.1177/10760296221117482

Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis

Clin Appl Thromb Hemost. 2022 Jan-Dec:28:10760296221117482. doi: 10.1177/10760296221117482.

Authors

Arumugam Manoharan^{1

2}, Rosalie Gemmell³, Lauren Cavanaugh³, Noor Shadood³

Affiliations

¹ Southern Sydney Haematology, St George Private Hosipital, Sydney, Australia.
² Faculty of Health, Medicine & Applied Sciences, 8691University of Wollongong, Wollongong, New South Wales, Australia.
³ Department of Haematology, ST. George Hospital, Sydney, Australia.

Abstract

Routine use of WBPA studies enables safe and effective risk-adapted thromboprophylaxis in MPN patients, irrespective of the underlying driver mutation and their risk predicted by the IPSET- thrombosis criteria.

Keywords: myeloproliferative neoplasms; risk assessment; thromboprophylaxis; thrombosis.

MeSH terms

Anticoagulants
Humans
Myeloproliferative Disorders* / complications
Myeloproliferative Disorders* / genetics
Neoplasms*
Platelet Aggregation
Risk Assessment
Thrombosis* / genetics
Thrombosis* / prevention & control
Venous Thromboembolism*

Substances

Anticoagulants